產品
Merck and Moderna's cancer vaccine is customized for each patient's tumor
Drug Discovery Trends reports that the Merck and Moderna cancer vaccine is customized to each individual patient's tumor.
文章預覽
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The companies are investigating the vaccine as a combination treatment with Merck’s Keytruda, a monoclonal antibody that targets the PD-1 receptor on T-cells, breaking a pathway that cancer uses to evade the immune system. The FDA granted the combination Breakthrough Therapy designation in 2023 and the companies noted that they plan to engage with regulators to pursue app…